Iterum Therapeutics Plc operates as a pharmaceutical company, which engages in the development and commercialization of sulopenem. The company was founded by Corey N. Fishman on June 24, 2015 and ...
Iterum reported a net loss of $6.6 million for Q4 and $24.8 million for full-year 2024. On a non-GAAP basis, the net loss was $3.1 million for Q4 and $17.6 million for the year, showing a ...
Hosted on MSN1mon
Iterum Therapeutics faces Nasdaq non-compliance issueIterum Therapeutics plc (NASDAQ:ITRM), a pharmaceutical company with a market capitalization of $53.43 million, has reported a regulatory compliance issue with the Nasdaq Stock Market.
Try Now>> See today’s best-performing stocks on TipRanks >> Iterum Therapeutics NewsMORE Related Stocks Indices Commodities Currencies Stocks ...
Piero Cingari FDA Approval Of Orlynvah For Urinary Tract Infections Marks Milestone For Iterum, Paves Way For New Strategic Partnerships Iterum Therapeutics' Orlynvah receives FDA approval for ...
ORLYNVAHTM Approved by FDA in Q4 2024— --Extended Cash Runway-- --Company to host conference call today at 8:30amET-- DUBLIN and CHICAGO, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics ...
Future of Healthcategory· October 25, 2024 US FDA approves Iterum's treatment for urinary infection The U.S. Food and Drug Administration has approved Iterum Therapeutics' oral antibiotic to ...
ORLYNVAHTM Approved by FDA in Q4 2024— --Extended Cash Runway-- --Company to host conference call today at 8:30amET-- DUBLIN and CHICAGO, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback